CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy
CPT: Pharmacometrics & Systems Pharmacology, 2017 MJ Garrido, P Berraondo, IF Trocóniz
openaire +3 more sources
Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec. [PDF]
CPT Pharmacometrics Syst PharmacolLi Y +7 more
europepmc +1 more source
Optimizing Venous Thromboembolism Prophylaxis in Burn Patients Using Enoxaparin Through PBPK Modeling. [PDF]
CPT Pharmacometrics Syst PharmacolMim SR, Yellepeddi VK, Azeredo FJ.
europepmc +1 more source
Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer. [PDF]
CPT Pharmacometrics Syst PharmacolYuan D +17 more
europepmc +1 more source
PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With Microdosing. [PDF]
CPT Pharmacometrics Syst PharmacolBurlot C +6 more
europepmc +1 more source
Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling. [PDF]
CPT Pharmacometrics Syst PharmacolZhang S +9 more
europepmc +1 more source
Evaluating Preclinical-to-Human Bioavailability Classification Using Smooth ROC Curve Estimation. [PDF]
CPT Pharmacometrics Syst PharmacolErdoğan MS.
europepmc +1 more source
Quantitative Evaluation of Model-Informed Drug Development Implementation in China's Approved Innovative Drugs: From Policy to Practice (2018-2024). [PDF]
CPT Pharmacometrics Syst PharmacolLi J, Wang Z, Wei C, He R, Yao Q.
europepmc +1 more source
Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018 openaire +2 more sources
MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications. [PDF]
CPT Pharmacometrics Syst PharmacolJavidi M +6 more
europepmc +1 more source